|
1
|
Ramakrishnan R, Antonia S and Gabrilovich
DI: Combined modality immunotherapy and chemotherapy: A new
perspective. Cancer Immunol Immunother. 57:1523–1529. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nowak AK, Lake RA and Robinson BW:
Combined chemoimmunotherapy of solid tumours: Improving vaccines?
Adv Drug Deliv Rev. 58:975–990. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Banchereau J and Steinman RM: Dendritic
cells and the control of immunity. Nature. 392:245–252. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Palucka K and Banchereau J: Cancer
immunotherapy via dendritic cells. Nat Rev Cancer. 12:265–277.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Galluzzi L, Senovilla L, Vacchelli E,
Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E,
Zitvogel L and Kroemer G: Trial watch: Dendritic cell-based
interventions for cancer therapy. Oncoimmunology. 1:1111–1134.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Podrazil M, Horvath R, Becht E, Rozkova D,
Bilkova P, Sochorova K, Hromadkova H, Kayserova J, Vavrova K,
Lastovicka J, et al: Phase I/II clinical trial of dendritic-cell
based immunotherapy (DCVAC/PCa) combined with chemotherapy in
patients with metastatic, castration-resistant prostate cancer.
Oncotarget. 6:18192–18205. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fucikova J, Kralikova P, Fialova A,
Brtnicky T, Rob L, Bartunkova J and Spísek R: Human tumor cells
killed by anthracyclines induce a tumor-specific immune response.
Cancer Res. 71:4821–4833. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hato SV, Khong A, de Vries IJ and
Lesterhuis WJ: Molecular pathways: The immunogenic effects of
platinum-based chemo-therapeutics. Clin Cancer Res. 20:2831–2837.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Spisek R, Charalambous A, Mazumder A,
Vesole DH, Jagannath S and Dhodapkar MV: Bortezomib enhances
dendritic cell (DC)-mediated induction of immunity to human myeloma
via exposure of cell surface heat shock protein 90 on dying tumor
cells: Therapeutic implications. Blood. 109:4839–4845. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Galluzzi L, Kepp O and Kroemer G:
Immunogenic cell death in radiation therapy. Oncoimmunology.
2:e265362013. View Article : Google Scholar
|
|
11
|
Weiss EM, Frey B, Rödel F, Herrmann M,
Schlücker E, Voll RE, Fietkau R and Gaipl US: Ex vivo- and in
vivo-induced dead tumor cells as modulators of antitumor responses.
Ann NY Acad Sci. 1209:109–117. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Frey B, Rubner Y, Kulzer L, Werthmöller N,
Weiss EM, Fietkau R and Gaipl US: Antitumor immune responses
induced by ionizing irradiation and further immune stimulation.
Cancer Immunol Immunother. 63:29–36. 2014. View Article : Google Scholar
|
|
13
|
Fucikova J, Moserova I, Truxova I,
Hermanova I, Vancurova I, Partlova S, Fialova A, Sojka L, Cartron
PF, Houska M, et al: High hydrostatic pressure induces immunogenic
cell death in human tumor cells. Int J Cancer. 135:1165–1177. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Emens LA: Chemoimmunotherapy. Cancer J.
16:295–303. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ménard C, Martin F, Apetoh L, Bouyer F and
Ghiringhelli F: Cancer chemotherapy: Not only a direct cytotoxic
effect, but also an adjuvant for antitumor immunity. Cancer Immunol
Immunother. 57:1579–1587. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
van Dodewaard-de Jong JM, Verheul HM,
Bloemendal HJ, de Klerk JM, Carducci MA and van den Eertwegh AJ:
New treatment options for patients with metastatic prostate cancer:
What is the optimal sequence? Clin Genitourin Cancer. 13:271–279.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Machiels JP, Reilly RT, Emens LA, Ercolini
AM, Lei RY, Weintraub D, Okoye FI and Jaffee EM: Cyclophosphamide,
doxorubicin, and paclitaxel enhance the antitumor immune response
of granulocyte/macrophage-colony stimulating factor-secreting
whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res.
61:3689–3697. 2001.PubMed/NCBI
|
|
18
|
Malvicini M, Rizzo M, Alaniz L, Piñero F,
García M, Atorrasagasti C, Aquino JB, Rozados V, Scharovsky OG,
Matar P, et al: A novel synergistic combination of cyclophosphamide
and gene transfer of interleukin-12 eradicates colorectal carcinoma
in mice. Clin Cancer Res. 15:7256–7265. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tannock IF, de Wit R, Berry WR, Horti J,
Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, et
al; TAX 327 Investigators. Docetaxel plus prednisone or
mitoxantrone plus prednisone for advanced prostate cancer. N Engl J
Med. 351:1502–1512. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Petrylak DP, Tangen CM, Hussain MH, Lara
PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M,
et al: Docetaxel and estramustine compared with mitoxantrone and
prednisone for advanced refractory prostate cancer. N Engl J Med.
351:1513–1520. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kantoff PW, Higano CS, Shore ND, Berger
ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims
RB, et al; IMPACT Study Investigators. Sipuleucel-T immunotherapy
for castration-resistant prostate cancer. N Engl J Med.
363:411–422. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Reinis M, Indrová M, Mendoza L, Mikysková
R, Bieblová J, Bubeník J and Símová J: HPV16-associated tumours:
Therapy of surgical minimal residual disease with dendritic
cell-based vaccines. Int J Oncol. 25:1165–1170. 2004.PubMed/NCBI
|
|
23
|
Reinis M, Stepanek I, Simova J, Bieblova
J, Pribylova H, Indrova M and Bubenik J: Induction of protective
immunity against MHC class I-deficient, HPV16-associated tumours
with peptide and dendritic cell-based vaccines. Int J Oncol.
36:545–551. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Indrová M, Reinis M, Bubeník J, Jandlová
T, Bieblová J, Vonka V and Velek J: Immunogenicity of dendritic
cell-based HPV16 E6/E7 peptide vaccines: CTL activation and
protective effects. Folia Biol (Praha). 50:184–193. 2004.
|
|
25
|
Lin KY, Guarnieri FG, Staveley-O'Carroll
KF, Levitsky HI, August JT, Pardoll DM and Wu TC: Treatment of
established tumors with a novel vaccine that enhances major
histocompatibility class II presentation of tumor antigen. Cancer
Res. 56:21–26. 1996.PubMed/NCBI
|
|
26
|
Foster BA, Gingrich JR, Kwon ED, Madias C
and Greenberg NM: Characterization of prostatic epithelial cell
lines derived from transgenic adenocarcinoma of the mouse prostate
(TRAMP) model. Cancer Res. 57:3325–3330. 1997.PubMed/NCBI
|
|
27
|
Lutz MB, Kukutsch N, Ogilvie AL, Rössner
S, Koch F, Romani N and Schuler G: An advanced culture method for
generating large quantities of highly pure dendritic cells from
mouse bone marrow. J Immunol Methods. 223:77–92. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Stepanek I, Indrova M, Bieblova J,
Fucikova J, Spisek R, Bubenik J and Reinis M: Effects of
5-azacytidine and trichostatin A on dendritic cell maturation. J
Biol Regul Homeost Agents. 25:517–529. 2011.
|
|
29
|
Yi AK and Krieg AM: CpG DNA rescue from
anti-IgM-induced WEHI-231 B lymphoma apoptosis via modulation of I
kappa B alpha and I kappa B beta and sustained activation of
nuclear factor-kappa B/c-Rel. J Immunol. 160:1240–1245.
1998.PubMed/NCBI
|
|
30
|
Reinis M, Símová J, Indrová M, Bieblová J,
Pribylová H, Moravcová S, Jandlová T and Bubeník J: Immunization
with MHC class I-negative but not -positive HPV16-associated tumour
cells inhibits growth of MHC class I-negative tumours. Int J Oncol.
30:1011–1017. 2007.PubMed/NCBI
|
|
31
|
Indrová M, Símová J, Bieblová J, Bubeník J
and Reinis M: NK1.1+ cells are important for the
development of protective immunity against MHC I-deficient,
HPV16-associated tumours. Oncol Rep. 25:281–288. 2011.
|
|
32
|
Bubenik J, Zeuthen J, Indrova M,
Bubenikova D and Simova J: Kinetics and function of
peritoneal-exudate cells during local IL-2 gene-therapy of cancer.
Int J Oncol. 4:13–16. 1994.PubMed/NCBI
|
|
33
|
Indrová M, Mikysková R, Jandlová T, Vonka
V, Bubeník J and Bieblová J: Adjuvant cytokine treatment of minimal
residual disease after surgical therapy in mice carrying
HPV16-associated tumours: Cytolytic activity of spleen cells from
tumour regressors. Folia Biol (Praha). 49:217–222. 2003.
|
|
34
|
Frey B, Janko C, Ebel N, Meister S,
Schlücker E, Meyer-Pittroff R, Fietkau R, Herrmann M and Gaipl US:
Cells under pressure - treatment of eukaryotic cells with high
hydrostatic pressure, from physiologic aspects to pressure induced
cell death. Curr Med Chem. 15:2329–2336. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Adkins I, Fucikova J, Garg AD, Agostinis P
and Špíšek R: Physical modalities inducing immunogenic tumor cell
death for cancer immunotherapy. Oncoimmunology. 3:e9684342014.
View Article : Google Scholar
|
|
36
|
Martini M, Testi MG, Pasetto M, Picchio
MC, Innamorati G, Mazzocco M, Ugel S, Cingarlini S, Bronte V,
Zanovello P, et al: IFN-gamma-mediated upmodulation of MHC class I
expression activates tumor-specific immune response in a mouse
model of prostate cancer. Vaccine. 28:3548–3557. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Okamoto M and Sato M: Toll-like receptor
signaling in anti-cancer immunity. J Med Invest. 50:9–24.
2003.PubMed/NCBI
|
|
38
|
Reinis M, Símová J, Indrová M, Bieblová J
and Bubeník J: CpG oligodeoxynucleotides are effective in therapy
of minimal residual tumour disease after chemotherapy or surgery in
a murine model of MHC class I-deficient, HPV16-associated tumours.
Int J Oncol. 30:1247–1251. 2007.PubMed/NCBI
|
|
39
|
Spranger S, Javorovic M, Bürdek M, Wilde
S, Mosetter B, Tippmer S, Bigalke I, Geiger C, Schendel DJ and
Frankenberger B: Generation of Th1-polarizing dendritic cells using
the TLR7/8 agonist CL075. J Immunol. 185:738–747. 2010. View Article : Google Scholar : PubMed/NCBI
|
